Clinical trials in Latvia

Latvia is actively involved in clinical research addressing cardiovascular diseases, with studies focusing on conditions such as acute coronary syndrome, acute myocardial infarction, atrial fibrillation, and chronic heart failure. These trials evaluate novel anticoagulants, antiplatelet therapies, and treatments aimed at reducing the risk of stroke and systemic embolism in patients with various forms of cardiovascular disease. Research also explores interventions for atherosclerotic cardiovascular disease, particularly in patients with chronic kidney disease and systemic inflammation.

• Prevention of ischemic stroke following acute non-cardioembolic events
• Reduction of major adverse cardiovascular events in post-myocardial infarction patients
• Management of atrial fibrillation in patients unsuitable for oral anticoagulation
• Treatment of heart failure with preserved or mildly reduced ejection fraction

These studies aim to improve outcomes for patients with complex cardiovascular conditions by testing innovative therapeutic approaches and optimizing existing treatment strategies.

Clinical trials in Latvia encompass a broad spectrum of oncological research, investigating treatments for non-small cell lung cancer, acute myeloid leukemia, glioblastoma, bladder cancer, and various other malignancies. Studies evaluate the efficacy of immunotherapies, targeted therapies, and combination regimens in both adult and pediatric populations. Research includes neoadjuvant and adjuvant treatment approaches, as well as maintenance therapies for advanced and metastatic cancers.

• Immunotherapy combinations for muscle invasive and non-muscle invasive bladder cancer
• Targeted therapies for metastatic hormone-sensitive and castration-resistant prostate cancer
• Novel agents for newly diagnosed glioblastoma multiforme
• Treatment strategies for pediatric acute myeloid leukemia with specific genetic markers

The focus is on improving survival rates, disease-free survival, and quality of life for cancer patients through innovative treatment protocols and personalized medicine approaches.

Research in immune system diseases and inflammatory conditions forms a significant part of Latvia's clinical trial landscape. Studies investigate treatments for rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and inflammatory bowel diseases including Crohn's disease and ulcerative colitis. These trials evaluate the safety and efficacy of biologic agents, small molecule inhibitors, and novel immunomodulatory therapies in patients with moderate to severe disease activity.

• JAK inhibitors for rheumatoid arthritis in methotrexate-inadequate responders
• Maintenance therapy for moderately to severely active Crohn's disease
• Biologic agents for moderate to severe ulcerative colitis
• Novel treatments for systemic lupus erythematosus with multi-organ involvement

These studies aim to achieve clinical remission, reduce disease activity, and improve long-term outcomes for patients with chronic inflammatory and autoimmune disorders.

Latvia participates in clinical trials addressing respiratory tract diseases, with particular emphasis on chronic obstructive pulmonary disease, asthma, and community-acquired pneumonia. Research evaluates inhaled therapies, oral medications, and combination treatments aimed at reducing exacerbation rates and improving lung function. Studies also investigate treatments for pulmonary arterial hypertension and bronchiectasis.

• Novel inhaled therapies for moderate to severe COPD
• Add-on treatments for asthma inadequately controlled on standard therapy
• Antibiotics for severe community-acquired bacterial pneumonia
• Oral inhalation therapies for pulmonary arterial hypertension

The research focuses on improving respiratory function, reducing hospitalizations, and enhancing quality of life for patients with chronic and acute respiratory conditions.

Clinical research in nervous system diseases encompasses studies on multiple sclerosis, epilepsy, amyotrophic lateral sclerosis, and peripheral neuropathies. Trials evaluate disease-modifying therapies for relapsing and progressive forms of multiple sclerosis, antiepileptic drugs for focal-onset and generalized seizures, and treatments for rare neurological conditions such as chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

• Long-term safety and efficacy of treatments for relapsing multiple sclerosis
• Novel antiepileptic drugs for focal-onset seizures and developmental epileptic encephalopathies
• Therapies for Dravet syndrome and Lennox-Gastaut syndrome
• Treatment approaches for chronic inflammatory demyelinating polyneuropathy

These studies aim to reduce disease progression, control symptoms, and improve neurological function in patients with debilitating neurological conditions.

Latvia contributes to clinical research in ophthalmology, with studies focusing on neovascular age-related macular degeneration, diabetic macular edema, geographic atrophy, and retinal vein occlusion. Research evaluates intravitreal therapies, including anti-VEGF agents and novel biologics, aimed at preserving or improving visual acuity. Studies also investigate the long-term effects of diabetes treatments on diabetic retinopathy.

• Higher-dose aflibercept for macular edema secondary to retinal vein occlusion
• Novel intravitreal agents for diabetic macular edema
• Long-term safety of therapies for geographic atrophy
• Prevention of diabetic retinopathy progression in type 2 diabetes

The focus is on preventing vision loss, improving visual outcomes, and establishing long-term safety profiles for ophthalmic interventions.

Research in dermatology includes trials on atopic dermatitis, psoriasis, prurigo nodularis, and bullous pemphigoid. Studies evaluate biologic therapies and small molecule inhibitors for moderate to severe skin conditions, with endpoints focusing on symptom reduction, particularly pruritus, and improvement in skin lesions. The research addresses both common and rare dermatological conditions requiring systemic treatment.

• Biologic agents for moderate to severe plaque psoriasis
• Novel treatments for prurigo nodularis focusing on itch reduction
• Therapies for moderate to severe atopic dermatitis
• Management strategies for bullous pemphigoid

These trials aim to achieve skin clearance, reduce symptom burden, and improve quality of life for patients with chronic and acute dermatological conditions.

Clinical trials in metabolic diseases focus on type 2 diabetes, obesity, hypercholesterolemia, and hypertriglyceridemia. Research evaluates novel glucose-lowering agents, lipid-modifying therapies, and combination treatments for patients inadequately controlled on standard therapy. Studies also investigate treatments for severe hypertriglyceridemia and the cardiovascular effects of metabolic interventions.

• Combination therapies for type 2 diabetes inadequately controlled on standard treatment
• Novel agents for severe hypertriglyceridemia
• Lipid-modifying therapies in patients with atherosclerotic cardiovascular disease
• Long-term safety assessment of diabetes medications on diabetic retinopathy

The research aims to improve glycemic control, optimize lipid profiles, and reduce cardiovascular risk in patients with metabolic disorders.

Latvia participates in studies addressing digestive system diseases, including Crohn's disease, ulcerative colitis, gastroparesis, and acute liver failure. Research evaluates biologic therapies, small molecules, and cell-based treatments for inflammatory bowel diseases, with endpoints including clinical remission and endoscopic response. Studies also investigate novel approaches for acute-on-chronic liver failure in cirrhotic patients.

• Maintenance therapy for moderately to severely active inflammatory bowel disease
• Induction and maintenance treatments for Crohn's disease
• Novel therapies for idiopathic and diabetic gastroparesis
• Cell-based therapy for acute-on-chronic liver failure

These trials focus on achieving and maintaining remission, improving gastrointestinal symptoms, and reducing the need for surgical interventions in patients with chronic digestive disorders.

Clinical research in infectious diseases includes studies on complicated urinary tract infections, acute pyelonephritis, diabetic foot infections, and community-acquired pneumonia. Trials evaluate novel antibiotics and antimicrobial agents for both common and resistant bacterial infections, including hospital-acquired and ventilator-associated pneumonia. Research also addresses complicated intra-abdominal infections and severe bacterial skin infections.

• Novel antibiotics for diabetic foot infections
• Treatment of complicated urinary tract infections and acute pyelonephritis
• Therapies for severe community-acquired bacterial pneumonia
• Management of hospital-acquired and ventilator-associated pneumonia

The focus is on improving clinical response rates, reducing treatment duration, and addressing antimicrobial resistance in serious bacterial infections.

Research in viral diseases includes studies on COVID-19 and prevention of common viral infections. Clinical trials evaluate antiviral therapies for high-risk COVID-19 outpatients, focusing on reducing hospitalization and mortality. Studies also investigate vaccines for prevention of measles, mumps, rubella, and varicella infections in healthy volunteers.

• Antiviral treatments for COVID-19 in high-risk outpatients
• Reduction of hospitalization in patients with acute lower respiratory infections
• Vaccine studies for prevention of common childhood viral diseases

These trials aim to improve outcomes in viral infections through both therapeutic interventions and preventive strategies.

Clinical trials in endocrine disorders focus on congenital adrenal hyperplasia, growth hormone deficiency, acromegaly, Graves' disease, and thyroid eye disease. Research evaluates hormone replacement therapies, steroid-sparing agents, and treatments for endocrine-related complications. Studies include both pediatric and adult populations with various hormonal imbalances requiring long-term management.

• Glucocorticoid-sparing therapies for classic congenital adrenal hyperplasia
• Growth hormone therapy in children with short stature
• Novel treatments for thyroid eye disease
• Management of acromegaly and Graves' disease

The research aims to optimize hormone levels, reduce treatment burden, and improve quality of life for patients with endocrine disorders.

Latvia participates in research on blood disorders, including hemophilia A and primary immune thrombocytopenia. Studies evaluate novel therapies for bleeding disorders, both in patients with and without inhibitors, and treatments for immune-mediated platelet destruction. Research focuses on improving hemostasis, reducing bleeding episodes, and managing complications of hematological conditions.

• Novel therapies for hemophilia A with and without inhibitors
• Treatment approaches for primary immune thrombocytopenia
• Management of bleeding complications in hematological disorders

These trials aim to improve bleeding control, reduce treatment frequency, and enhance quality of life for patients with chronic blood disorders.

Clinical research in musculoskeletal diseases includes studies on rheumatoid arthritis, psoriatic arthritis, post-menopausal osteoporosis, and pediatric lower limb spasticity caused by cerebral palsy. Trials evaluate disease-modifying therapies, bone-protective agents, and treatments for spasticity. Research addresses both inflammatory joint diseases and conditions affecting bone density and muscle function.

• JAK inhibitors and biologic therapies for inflammatory arthritis
• Bone-protective agents for post-menopausal osteoporosis
• Management of pediatric lower limb spasticity in cerebral palsy

The focus is on reducing joint damage, preventing fractures, and improving mobility and function in patients with musculoskeletal disorders.

Research in psychiatry includes clinical trials on major depressive disorder, evaluating novel antidepressant therapies and treatment approaches for patients with moderate to severe depression. Studies focus on improving depressive symptoms, achieving remission, and enhancing overall mental health outcomes.

• Novel therapies for major depressive disorder
• Treatment approaches for moderate to severe depression

These trials aim to improve response rates, reduce symptom burden, and enhance quality of life for patients with psychiatric conditions.